16Dec 2022
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma

EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma

Glioblastoma (GBM) is adults' most lethal primary brain tumor and harbors a subpopulation of glioma stem cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), a histone lysine methyltransferase, is deeply involved in GSC's stemness maintenance. Overexpression of HP1BP3 enhances the proliferation, self-renewal and temozolomide (TMZ) resistance of GBM cells. Importantly, inhibition of WNT7B autocrine via LGK974 effectively reverses the TMZ resistance. The study clarifies a new oncogenic mechanism of EZH2 that interacts with HP1BP3 and epigenetically activates WNT7B, thereby promoting TMZ resistance in GSCs. The results provide a rationale for targeting the WNT/β-catenin pathway as a promising strategy to overcome TMZ resistance in GSCs.

  • #oncology

Like

Save

Share